Acute Myeloid Leukemia (AML) is an aggressive form of leukemia, mainly affecting the adult population, and within this subset, affecting males more than females. Approximately 23,000 individuals are expected to be diagnosed with AML over next year in the US, Japan and Europe. The likelihood of survival of AML patients is most easily defined by the genotype initiating the disease. The prognosis defined in this way can range from very poor to extended disease free survival in the most treatable cases. This brief provides an overview of the AML market, exploring the epidemiology and the most widely used treatment approaches. Subsequent sections of the brief examine the predicted evolution of the AML market with the release of some long awaited drugs and the future perspectives of the drug market.
